uniQure N.V.
QURE
NASDAQ
IPO2014
about QURE
uniQure N.V. is a biotechnology company specializing in gene therapy treatments, with its primary focus on developing EvoxTM, an innovative treatment for hemophilia A that addresses the root cause of the disease by delivering a healthy copy of the factor IX gene.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $20.90 | $21.07 | $16.21 | $1.5B | 17.57M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$1.38 | n/a | 268.79 | -1378.95% | -2175.87% | 0% |